SARCLISA

sanofi-aventis canada inc🇨🇦 Health Canada

Approval Id: aaeb00899ab666e7
Drug Approval Canada Name: SARCLISA
Product Name: SARCLISA
Status: Marketed
Status Date: 2020-07-03
Original Market Date: 2020-07-03
Din: 02498243
Drug Class: Human
Dosage Form: Solution
Route Of Administration: Intravenous
Schedule: Prescription , Schedule D
Ahfs: 10:00.00
Atc Original: L01FC02 ISATUXIMAB
Atc Name: l 01 fc 02
Aig Number: 0162194001
Company Name: sanofi-aventis canada inc
Company Address: 1755 Steeles Avenue West, Toronto, Ontario, Canada, M2R 3T4

ISATUXIMAB

500 MG / 25 ML

Authorized

Agency

Health Canada

Country

🇨🇦

Approval Date

Jul 4, 2025

Approval ID

aaeb00899ab666e7

Type

Standard